|
| 1 |
|
Conditions listed in this trial |
|
|
Breast Cancer |
|
|
Extragonadal Germ Cell Tumor |
|
|
Gestational Trophoblastic Tumor |
|
|
Kidney Cancer |
|
|
Lung Cancer |
|
|
Neuroblastoma |
|
|
Ovarian Cancer |
|
|
Sarcoma |
|
|
Testicular Germ Cell Tumor |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Breast Neoplasms |
|
|
Carcinoma, Renal Cell |
|
|
Gestational Trophoblastic Neoplasms |
|
|
Kidney Neoplasms |
|
|
Lung Neoplasms |
|
|
Neoplasms, Germ Cell and Embryonal |
|
|
Ovarian Neoplasms |
|
|
Trophoblastic Neoplasms |
|
| 3 |
|
More general conditions related to this trial |
|
|
Adenocarcinoma |
|
|
Adnexal Diseases |
|
|
Breast Diseases |
|
|
Carcinoma |
|
|
Endocrine Gland Neoplasms |
|
|
Endocrine System Diseases |
|
|
Genital Diseases, Female |
|
|
Genital Neoplasms, Female |
|
|
Gonadal Disorders |
|
|
Kidney Diseases |
|
|
Lung Diseases |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
|
Neoplasms by Site |
|
|
Neoplasms, Connective and Soft Tissue |
|
|
Neoplasms, Glandular and Epithelial |
|
|
Neoplasms, Nerve Tissue |
|
|
Neoplasms, Neuroepithelial |
|
|
Neuroectodermal Tumors |
|
|
Neuroectodermal Tumors, Primitive |
|
|
Neuroectodermal Tumors, Primitive, Peripheral |
|
|
Ovarian Diseases |
|
|
Pregnancy Complications |
|
|
Pregnancy Complications, Neoplastic |
|
|
Respiratory Tract Diseases |
|
|
Respiratory Tract Neoplasms |
|
|
Skin Diseases |
|
|
Thoracic Neoplasms |
|
|
Urogenital Neoplasms |
|
|
Urologic Diseases |
|
|
Urologic Neoplasms |
|
| 4 |
|
Interventions listed in this trial |
|
|
aldesleukin |
|
|
busulfan |
|
|
carboplatin |
|
|
cyclophosphamide |
|
|
etoposide |
|
|
filgrastim |
|
|
ifosfamide |
|
|
paclitaxel |
|
|
sargramostim |
|
|
therapeutic autologous lymphocytes |
|
| 5 |
|
More general drug interventions related to this trial |
|
|
Alkylating Agents |
|
|
Anti-HIV Agents |
|
|
Anti-Infective Agents |
|
|
Anti-Retroviral Agents |
|
|
Antimitotic Agents |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Alkylating |
|
|
Antineoplastic Agents, Phytogenic |
|
|
Antirheumatic Agents |
|
|
Antiviral Agents |
|
|
Immunologic Factors |
|
|
Immunosuppressive Agents |
|
|
Mitosis Modulators |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Myeloablative Agonists |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Therapeutic Uses |
|
|
Tubulin Modulators |
|
| 6 |
|
Sponsors listed in this trial |
|
|
Barbara Ann Karmanos Cancer Institute |
